ABSTRACT
Background Metabolites in plasma form biosignatures of a range of common complex human diseases. Mapping the genetic architecture and discovering variants with pleiotropic effects across metabolites can reveal underlying mechanisms and potential targets for personalized interventions.
Methods We performed univariate and multivariate genome-wide association studies (GWAS) on the Nightingale panel of 249 circulating plasma metabolic markers, across 207,836 White British UK Biobank participants (mean age 57.4 years, 53.7% female), with replication conducted across 27,509 UK Biobank participants with different ancestries, and 92,661 Estonian Biobank participants (mean age 50.9 years, 65.7% female). We investigated rare variation through whole exome sequencing gene burden tests, quantified genetic architectures through Gaussian mixture modelling, analysed the causal role of body mass index (BMI) through Mendelian randomization, and performed genome-wide interaction analyses with sex.
Results We discovered 14,837 loci (497 unique), with shared and distinct effects on cardiometabolic traits, with high replication rates across populations. The loci explained over 70% of genetic variance for fatty acids. Findings from common and rare variant gene tests converged on lipid homeostasis pathways. There was strong evidence for causal effects of BMI on cholesterol and amino acid levels. We discovered 31 loci interacting with sex, which mapped to genes involved in cholesterol processing, and to cardiometabolic conditions with sex differences in prevalence.
Discussion The findings offer new insights into the genetic architecture of circulating metabolites, revealing novel loci and plausible sex-specific molecular mechanisms of lipid metabolism. This improved understanding of the molecular biology of metabolism lays a foundation for personalized prevention and treatment strategies.
Competing Interest Statement
OAA has received speaker fees from Lundbeck, Janssen, Otsuka, and Sunovion and is a consultant to Cortechs.ai. and Precision Health. AMD was a Founder of and holds equity in CorTechs Labs, Inc, and serves on its Scientific Advisory Board. He is also a member of the Scientific Advisory Board of Human Longevity, Inc. (HLI), and the Mohn Medical Imaging and Visualization Centre in Bergen, Norway. He receives funding through a research agreement with General Electric Healthcare (GEHC). The terms of these arrangements have been reviewed and approved by the University of California, San Diego in accordance with its conflict-of-interest policies. OF is a consultant to Precision Health. All other authors report no potential conflicts of interest.
Funding Statement
The authors were funded by the Research Council of Norway (273291, 273446, 296030, 324252, 324499, 326813), NordForsk (164218), the South-Eastern Norway Regional Health Authority 2017-112, Estonian Research Council (grant PSG615), The University of Tartu grant PLTGI24925, European Unions Horizon 2020 research and innovation program under grant agreement (CoMorMent) 847776, 964874 (RealMent).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UKB has received ethics approval from the National Health Service National Research Ethics Service (ref 11/NW/0382) and obtained informed consent from its participants. All EstBB participants have signed an informed consent form and the study was granted ethical approval from the Estonian Council on Bioethics and Human Research (24 March 2020, nr 1.1-12/624).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data incorporated in this work were gathered from public resources. All data described are available through UK Biobank, subject to approval from the UK Biobank access committee. See https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access for further details. The MOSTest code is available via https://github.com/precimed/mostest (GPLv3 license). GWAS summary statistics are uploaded to the NHGRI-EBI GWAS catalog (https://www.ebi.ac.uk/gwas/).
